philips onder vuur in amsterdam: investeerders eisen antwoorden over apneu-affaire
Amsterdam, donderdag, 25 juni 2026.
Philips staat vandaag voor de rechtbank in Amsterdam. Investeerders eisen een onafhankelijk onderzoek naar de terugroepactie van miljoenen slaapapparaten. Het defecte schuim in de apparaten zorgde wereldwijd voor ophef. Gebruikers meldden gezondheidsklachten. De koers van Philips daalde fors sinds 2021. Beleggers verloren miljarden. Ze twijfelen aan de timing van de communicatie van het concern. Er zijn signalen dat Philips al jaren eerder wist van het probleem. De uitspraak kan gevolgen hebben voor het management. Een schikking in de VS bood geen oplossing. De druk op de leiding blijft groot.
investors demand independent probe into philips’ cpap recall
Shareholders are demanding an independent investigation into Philips’ handling of its massive sleep apnea device recall. The hearing takes place today in Amsterdam’s Enterprise Chamber. Investors allege delayed disclosure of critical safety issues concerning the devices’ sound-dampening foam. They argue timely warnings could have prevented significant financial losses. The recall, announced in April 2021, impacted millions globally. Claimants believe internal signals were ignored years prior. The outcome may determine corporate liability and oversight reforms within the company [1].
longstanding concerns precede formal recall action
Legal representatives for shareholders state that complaints about the deteriorating foam existed as early as 2015 at a US-based Philips subsidiary. Regulatory body FDA previously warned this division about inadequate complaint handling processes. Despite these alerts, Philips executives reportedly failed to intervene decisively. Internal systems allegedly flagged the foam issue before leadership acknowledged its severity. Shareholder group VEB contends problems were evident since 2010, citing incidents like a three-year-old patient’s discolored filter. This suggests potential systemic failures predate public awareness [2][4].
financial fallout and executive scrutiny intensify pressure
The CPAP machine crisis triggered billions in losses and a sharp decline in Philips’ share value starting in April 2021. Investor groups including VEB, Vanguard, pension funds, and insurers now seek accountability. They question when senior management became aware of the risks. Current CEO Roy Jakobs led the responsible division during key periods under scrutiny. VEB specifically calls for Jakobs and chief legal officer Marnix van Ginneken to be sidelined. An independent official might manage future settlement negotiations to prevent conflicts of interest [3][5].
conflicting narratives on communication and risk assessment
Philips maintains its leadership recognized the situation’s gravity only around 2020–2021 and informed markets promptly thereafter. Company lawyers deny withholding information from investors. They assert no elevated health risks were detected internally before the recall decision. Former CEO Frans van Houten defended the recall choice, stating it was unavoidable at the time. Later studies concluded the foam posed no unacceptable health hazard according to Dutch Health Authority and FDA assessments. Philips emphasizes learning from the incident responsibly [1][2].
claims escalate amid stalled settlements and ongoing probes
Claim values linked to the affair now exceed five billion euros, though Philips anticipates lower liabilities. Previous settlements, such as a $1.1 billion agreement in the United States, did not resolve shareholder grievances. The current legal process focuses on governance failure rather than immediate compensation. Separate investigations by the U.S. Department of Justice and Securities and Exchange Commission continue. Philips expects conclusions from these inquiries in 2026. Today’s ruling won’t deliver a verdict but determines if deeper scrutiny proceeds [3][5].